Butyrate Supplements: Benefits, Forms, and What the Human Data Actually Shows
Butyrate might be the most interesting compound in gut health. Your gut bacteria make it, the cells lining your colon run on it, and it's become one of the most popular appetite-support supplements on the market for a reason.
This guide covers what butyrate does, how forms compared in a published human absorption trial, and exactly what tier of evidence backs each claim.
Butyrate has an established biological role and a growing human research base. Compare its forms, the outcomes actually measured and how the studies relate to our formula.
Butyrate is a short-chain fatty acid produced during microbial fermentation in the gut. It is an important fuel for colon-lining cells and is studied for signaling and metabolic effects. Supplying it in a supplement is a different intervention from changing the bacteria and foods that produce it.
What the human absorption comparison establishes
A 2025 randomized crossover study in 10 healthy men compared lysine butyrate, sodium butyrate and tributyrin, each supplying 786 mg butyric acid. Lysine and sodium produced greater systemic exposure and earlier peaks than tributyrin. The mean lysine peak was at the first post-dose blood sample, 20 minutes.
This is useful evidence that the tested forms behave differently in circulation. It does not establish an exact onset of appetite relief, superiority for a health condition, or how much reached the colon. The study’s butyric-acid-equivalent amount is not the same as our 500 mg BIOMEnd ingredient serving.
Human outcomes: promising findings and meaningful differences
Human butyrate evidence is broader than mouse experiments. A 45-day trial in type 2 diabetes found higher GLP-1 with sodium butyrate. An eight-week obesity trial reported favorable metabolic findings without a significant GLP-1 change. A 2026 trial found different weight and glucose results depending on diabetes status. Those differences are a reason to identify the tested form and population, not erase the positive findings.
A separate 2026 delivery experiment found hormone and appetite responses to a short-chain-fatty-acid mixture. It was not pure butyrate or an Ozzi drink, so its results cannot be attributed to our butyrate serving alone.
Read the studies
Open a study for its population, findings and relevance to our formula. The full research library includes additional primary studies and reviews.
Butyrate · 2025 · Human pharmacokinetic trial
10 healthy men; randomized crossover; lysine butyrate, sodium butyrate and tributyrin, each providing 786 mg butyric acid.
Lysine and sodium butyrate produced greater systemic exposure and earlier peak concentrations than tributyrin. The mean lysine-butyrate peak occurred at the first post-dose sample, 20 minutes.
Directly relevant form-specific absorption research. The lysine product was not a 500 mg dose, and this study did not measure GLP-1, appetite or snacking; do not describe it as proof of effects within 20 minutes.
Butyrate · 2017 · Human trial
60 adults with type 2 diabetes; four groups; sodium butyrate, inulin, both or placebo for 45 days.
Sodium butyrate alone and the butyrate–inulin combination increased GLP-1 compared with placebo. Several other changes were confined to combination treatment or comparisons within a group.
Direct human hormone evidence for sodium butyrate, not a trial of Ozzi’s L-lysine form. The associated experimental program used 600 mg sodium butyrate daily; keep inulin identified as a study co-intervention, not an Ozzi active.
Butyrate · 2025 · Human trial
50 adults with obesity; randomized trial; 600 mg sodium butyrate daily plus calorie restriction versus placebo plus the same diet for eight weeks.
The trial reported favorable metabolic and anthropometric changes alongside altered expression of energy-metabolism genes. Serum GLP-1 did not significantly change.
Benefits can be discussed without forcing a GLP-1 explanation. Some abstract results emphasize changes within treatment; do not present all as proven between-group effects.
Butyrate · 2026 · Human trial
46 adults, including 23 with type 2 diabetes; 1,875 mg sodium butyrate daily or placebo, with the same reduced-energy diet for 12 weeks.
In participants without diabetes, butyrate produced greater weight loss than placebo; in those with diabetes, weight changes were similar but triglycerides and a continuous-glucose-monitoring measure improved. The 2026 results suggest that benefits can depend on metabolic status.
Useful current human evidence with a diet co-intervention, small subgroups and a different butyrate form and dose. Not evidence of rapid snack suppression from 500 mg lysine butyrate.
Butyrate · 2026 · Human trial
Seven adults with obesity; three intervention visits; L-arginine alone, L-arginine plus sodium butyrate or no intervention before a standard meal.
The combination increased circulating GLP-1 relative to no intervention, while subjective hunger and fullness did not significantly change. The experiment was small and did not isolate butyrate’s contribution.
L-arginine is not L-lysine and is not an Ozzi ingredient. Use only as combination-mechanism context.
Butyrate · 2026 · Human trial
28 healthy adults; randomized crossover; a 230 mmol short-chain-fatty-acid mixture targeted to the small intestine or colon versus placebo.
Hormone and appetite responses differed by delivery site, with greater PYY after colonic delivery and greater GLP-1 after small-intestinal delivery. Both delivery conditions reduced reported appetite, more so with small-intestinal delivery.
New 2026 human gut-signaling evidence; a targeted mixed-SCFA intervention is not equivalent to a standard oral lysine-butyrate serving.
Butyrate · 2018 · Human trial
Nine lean men and 10 men with metabolic syndrome; 4 g sodium butyrate daily for four weeks; before–after pilot.
Insulin sensitivity improved in lean participants but not in those with metabolic syndrome. Brown-fat activity did not significantly increase in either group.
Important population-dependent finding; lack of a placebo-controlled treatment comparison limits causal certainty.
Butyrate · 2025 · Human trial
146 postmenopausal women in placebo or butyrate groups, plus 75 premenopausal reference participants; 570 mg sodium butyrate daily for 12 weeks.
Butyrate improved handgrip and physical-performance measures and reduced blood markers interpreted as related to intestinal barrier function. The authors linked these changes to a possible gut–muscle pathway.
The biomarkers are indirect evidence; avoid turning them into proof that Ozzi repairs a leaky gut or treats menopause.
Butyrate · 2022 · Human trial
53 people with type 1 diabetes, albuminuria and intestinal inflammation; 3.6 g sodium butyrate daily or placebo for 12 weeks.
Butyrate did not significantly improve the primary intestinal-inflammation marker or the measured kidney, glycemic, inflammatory or gastrointestinal outcomes. This shows that promising mechanisms do not translate uniformly across clinical settings.
Relevant counterevidence to blanket gut-repair or anti-inflammatory claims.
Butyrate · 2013 · Animal and mechanism study
Mouse probiotic experiments plus cultured intestinal L cells exposed to butyrate.
The probiotic intervention was associated with greater butyrate and GLP-1, and butyrate directly stimulated GLP-1 release in the cell experiments. This supports a plausible microbiota–metabolite–hormone pathway.
The whole-animal intervention was a probiotic, not an Ozzi-style butyrate supplement.
Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion.
Butyrate · 2012 · Animal and mechanism study
Primary intestinal cell cultures and mice lacking the SCFA receptors FFAR2 or FFAR3.
Short-chain fatty acids stimulated GLP-1 release, and receptor disruption reduced this response. The findings support a receptor-mediated link between intestinal fermentation products and hormone secretion.
Use as SCFA-receptor biology; do not assume every SCFA or oral formulation produces the same effect.
Butyrate · 2018 · Animal and mechanism study
Mice; oral versus intravenous butyrate, pair-feeding and vagotomy experiments.
Oral butyrate reduced food intake and influenced brain pathways involved in feeding; interrupting the vagus abolished key effects. Chronic treatment also improved fat oxidation and brown-fat activity.
Provides direct preclinical gut–brain rationale for appetite positioning, clearly labeled as animal research.
Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit.
Butyrate · 2009 · Animal and mechanism study
Caco-2 intestinal cell monolayers; butyrate exposure and AMPK-inhibition experiments.
Butyrate increased barrier resistance and promoted tight-junction assembly through an AMPK-linked process. Blocking AMPK prevented key barrier effects.
Mechanistic support for intestinal-barrier research, not a human gut-repair claim.
Butyrate · 2009 · Animal and mechanism study
Diet-induced obese mice; sodium butyrate at 5% of the diet.
Butyrate improved insulin sensitivity and energy expenditure and reduced adiposity in mice. In this experiment the prevention of obesity was not explained by lower food intake.
Useful reminder that metabolic benefits and appetite effects are separate endpoints and need not share one explanation.
Butyrate improves insulin sensitivity and increases energy expenditure in mice.
Butyrate · 2025 · Review
2025 semi-systematic review of animal and human butyrate research.
The review describes strong mechanistic interest but uneven translation to humans because delivery, absorption, metabolism and baseline health differ. It calls for better human trials while recognizing multiple plausible metabolic pathways.
Use as the broad review context alongside the newer 2026 trials. It is not a meta-analysis proving a uniform supplement effect.
Why we use L-lysine butyrate in Ozzi
We chose BIOMEnd L-lysine butyrate for our drink formulation. Each drink stick contains 500 mg of the ingredient alongside allulose, konjac glucomannan, African mango, ursolic acid and chromium. We describe each active separately on our ingredient page. Our capsules also contain L-lysine butyrate, within a proprietary blend; we do not assign the drink’s amount to capsules.
We built Ozzi for cravings and food noise, especially in the evening. Our ingredient research supports the formulation rationale, while a clinical trial of our finished formula remains future work. We do not claim a guaranteed 20-minute effect, proven treatment for a digestive condition or a predictable amount of weight loss.
Common questions
Does better absorption prove better appetite control?
No. Pharmacokinetic measurements show circulating exposure. Appetite ratings, food intake and clinical outcomes need separate trials.
Is the study amount the same as Ozzi’s serving?
No. The comparison supplied 786 mg butyric acid from each test product. Our drink lists 500 mg BIOMEnd L-lysine butyrate as an ingredient; those quantities are not interchangeable.
Are there human butyrate and GLP-1 studies?
Yes. Human trials include both positive and nonsignificant findings, with different forms, populations and interventions. The evidence is not limited to mice, and it does not establish the same response to every product.
Butyrate benefits and forms · Butyrate and GLP-1 research · BIOMEnd form guide · Butyrate study library
Explore our drink sticks · Explore our capsules · Ingredients and labels · Full research library